More than half of adults with overweight or obesity prescribed a GLP-1 discontinue their drug within 1 year, with discontinuation rates higher for those without type 2 diabetes, researchers reported ...

NEW YORK, NY / ACCESS Newswire / January 31, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about ...

NVO Investors with Losses Encouraged to Contact the FirmSan Francisco, California--(Newsfile Corp. - January 31, 2025) - Novo Nordisk A/S (NYSE: ...

Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But ...

With (almost) no fees and unlimited refunds for ATM charges, Novo business checking is a good option for small-business owners on the go. But Novo’s customer support is lacking, and you can’t ...

A/S, a global healthcare company specializing in diabetes care and other chronic conditions, has been at the forefront of the rapidly expanding GLP-1 market. With a market capitalization of $376.79 ...

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...

Veru said on Monday its experimental drug in combination with Novo Nordisk's weight-loss treatment Wegovy, helped preserve muscle in older patients with obesity, meeting the main goal of a mid-stage ...

Moderna and Novo Nordisk are once again in the bad books of the U.K.’s drug marketing watchdog. | Moderna and Novo Nordisk ...

Novo Nordisk was slammed by a U.K. trade group for not disclosing payments to health and patient groups, according to a draft ...

Novo Nordisk has reported 22% weight loss in people who received weekly amycretin injections for 36 weeks, triggering an 11% ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...